MedPath

Colorectal Cancer: Screening vs. Non-Screening

Completed
Conditions
Screening
Colorectal Cancer
Registration Number
NCT02727894
Lead Sponsor
Institute for Clinical and Experimental Medicine
Brief Summary

The purpose of this study is to determine whether colorectal cancer diagnosed by screening (primary screening colonoscopy, colonoscopy after immunochemical based faecal occult blood test) has more favourable clinical-pathological characteristics than colorectal cancer diagnosed for symptoms. We aimed to compare these two groups of patients at the time of diagnosis and confirm the efficiency of the screening programme.

Detailed Description

Multicentre prospective observational study. 12 centres across the Czech rep. included. Study approved by Ethical Committee.

All participants gave their informed signed consent. Each centre was assigned a unique ID number to distinguish between the locations in which patients were enrolled.

Patients informations were stored under identification number in secure internet database (RedCap) run by The International Clinical Research Center of St. Anne's University Hospital Brno.REDCap is a secure, web-based application designed to support data capture for research studies.

Statistical analysis was done with SAS, ver. 9.3. Descriptive statistics such as absolute and relative frequencies and median with 95 % confidence intervals were used. Differences between the screening and non-screening groups were compared using the Chi-square test or Fisher's exact test (categorical parameters) and Mann-Whitney test (continuous parameters). Results with a p-value \< 0.05 were considered statistically significant

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
276
Inclusion Criteria
  • newly diagnosed colorectal cancer
Exclusion Criteria
  • unsigned informed consent
  • mental disorder

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Colorectal Cancer Stage (pTNM)at time of diagnosis

Differences between colorectal cancer stage (0,I,II) in screening vs. non-screening group.

* 0. stage (Tis N0 M0)

* I. stage (T1-2 N0 M0)

* II. stage (T3-4 N0 M0)

* III. stage (T1-4 N1-2 M0)

* IV. stage (T1-4 N1-2 M1)

Stages 0,I II were considered to have better outcome

Secondary Outcome Measures
NameTimeMethod
Colorectal Cancer Resection Marginsafter surgery was performed

Difference between colorectal cancer resection margins (RX, R0, R1, R2) in screening vs. non-screening group.

* RX: cannot be identified

* R0: no cancer cells seen microscopically at the resection margin

* R1: cancer cells present microscopically at the resection margin (microscopic positive margin)

* R2: gross examination by the naked eye shows tumor tissue present at the resection margin (macroscopic positive margin)

Colorectal Cancer Metastasisat time of diagnosis

Differences between occurrence of colorectal cancer metastasis (MX, M0, M1) between screening vs. non-screening group.

* MX: cannot be measured

* M0: cancer has not spread to other parts of the body

* M1: cancer has spread to other parts of the body

Colorectal Cancer Gradeafter surgery was performed

Differences between colorectal cancer grade in screening vs. non-screening group.

* GX (cannot be identified)

* G1 (well diff.)

* G2 (moderately diff.)

* G3 (poorly diff.)

* G4 (undifferentiated)

Grades 1,2 were considered to have connection with lower stage

Colorectal Cancer Surgerytime between diagnosis and surgery, measured after surgery was performed

Median time between diagnosis and surgery.

Colorectal Cancer and Palliative Therapyduring treatment plan setting

Differences between neoadjuvant, adjuvant and systemic palliative therapy in screening vs. non-screening group.

Number of patients treated with palliative therapy in both groups.

Trial Locations

Locations (1)

Institute for Clinical and Experimental Medicine

🇨🇿

Praha, Czechia

© Copyright 2025. All Rights Reserved by MedPath